American Society of Transplant Surgeons 19th Annual State of the Art Winter Symposium Asts 2020

Delayed Bourse de Toronto  - 04/26 12:36:21 pm EDT 1.400 CAD -ane.41%

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium 12/16/2021 | 06:07am EDT DGAP-News: Sernova Corp. / Key give-and-take(s): Study results/Conference Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Wintertime Symposium 16.12.2021 / 12:05 The issuer is solely responsible for the content of this proclamation. LONDON, ONTARIO - Dec 16, 2021 - Sernova Corp. (TSX-5:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-phase regenerative medicine and jail cell therapy therapeutics company focused on developing a potential 'functional cure' for blazon ane diabetes (T1D) and other chronic diseases, is pleased to announce that Dr. Piotr Witkowski, main investigator of Sernova'southward Phase I/Ii clinical trial volition nowadays updated interim results from the ongoing condom, tolerability and efficacy study of Sernova'south Prison cell Pouch(TM) in a poster session at the American Lodge of Transplant Surgeons (ASTS) 22nd Almanac "Country of the Art" Wintertime Symposium on January 13, 2022. Dr. Witkowski'southward presentation entitled, A Modified Approach for Improved Islet Allotransplantation into the Pre-vascularized Sernova Jail cell Pouch(TM) device-preliminary results of the stage I and II clinical report at University of Chicago, volition be presented to more than 600 transplant professionals as part of Abstruse Session A, starting at 5:30 PM. Further details on the plan and registration can be plant on the ASTS Winter Symposium website: https://asts.org/events-meetings/winter-symposium The ASTS Winter Symposium is the aforementioned briefing where, in January 2021, Dr. Witkowski presented positive preliminary safety and efficacy information indicating that Sernova'south Prison cell Pouch(TM) transplanted with insulin producing cells in patients with type i diabetes showed persistent islet function and clinically meaningful improvement in measures of glucose control. ABOUT ASTS The American Society of Transplant Surgeons represents approximately ane,900 professionals, regulatory authorities and pharmaceutical representatives dedicated to excellence in transplantation surgery. ASTS advances the art and science of transplant surgery through patient care, inquiry, education, and advocacy. ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected homo cells and stem cell-derived cells) to better the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com. ABOUT SERNOVA'S CELL POUCH System The Jail cell Pouch, every bit office of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones equally required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small-scale and large creature models of diabetes and has been proven to provide a biologically uniform environment for insulin-producing cells in humans in a Canadian first-in-homo written report. Sernova is currently conducting a Phase I/Ii study at the Academy of Chicago. Positive initial results have been presented at several international scientific conferences. FOR FURTHER Data, PLEASE CONTACT: Corey Davis, Ph.D. LifeScience Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577 Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 world wide web.sernova.com FORWARD-LOOKING Data This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the visitor. Wherever possible, merely not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forrad-looking statements. These statements reflect direction'due south beliefs with respect to time to come events and are based on information currently available to management on the date such statements were made. Many factors could crusade Sernova'southward actual results, performances or achievements to not be as predictable, estimated or intended or to differ materially from those expressed or implied past the forward-looking statements independent in this news release. Such factors could include, but are non limited to, the company's power to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to behave all required preclinical and clinical studies for the company's Prison cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely ground; ability to in-license additional complementary technologies; power to execute its business organisation strategy and successfully compete in the marketplace; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company'due south quarterly and annual filings available on world wide web.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 16.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Annal at world wide web.dgap.de Language: English language Company: Sernova Corp. 700 Collip Circumvolve, Ste 114 N6G 4X8 London Canada Internet: https://world wide web.sernova.com/contact/ EQS News ID: 1258867 End of News DGAP News Service 1258867  sixteen.12.2021 � EQS 2021 All news about SERNOVA CORP. 04/19 SERNOVA : 2021 Fiscal Twelvemonth PU 04/19 SERNOVA : 2021 Fiscal Yr F/S PU 04/05 SERNOVA : Investor Deck - March 2022 PU 03/thirty SERNOVA : 2022 q1 PU 03/29 Sernova Corp. Reports Earnings Results for the First Quarter Ended Jan 31, 2022 CI 03/17 Sernova Corp. Announces Data Safety Monitoring Board Recommends Continuation of Stage one.. CI 03/17 Information Condom Monitoring Board Recommends Continuation of Phase ane/2 Clinical Trial with S.. AQ 02/24 Sernova Ranks Among Peak fifty Performing Companies on the 2022 TSX Venture List EQ 02/24 SERNOVA : Ranks Amidst Height 50 Performing Companies on the 2022 TSX Venture List PU 02/23 SERNOVA : CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS Concluded OCTOBER 31, 2021 AND 2020 .. PU More news		Financials Sales 2022 - - - Net income 2022 -9,36 Thousand -7,31 1000 -7,31 M Internet Debt 2022 - - - P/E ratio 2022 -40,6x Yield 2022 - Capitalization 373 K 292 M 291 Grand Capi. / Sales 2022 - Capi. / Sales 2023 - Nbr of Employees - Free-Float 97,4% Chart SERNOVA CORP. Duration : Menstruum : Full-screen chart Income Statement Evolution Consensus Sell Purchase Mean consensus OUTPERFORM Number of Analysts iii Final Close Price 1,42 CAD Average target price 2,92 CAD Spread / Boilerplate Target 105% EPS Revisions Managers and Directors Philip M. Toleikis President, Chief Executive Officer & Director David Swetlow Chief Financial Officer Frank A. Holler Chairman Delfina Siroen Senior Manager-Research & Evolution Frank Shannon Vice President-Clinical & Regulatory Sector and Competitors 1st jan. Capi. (M$) SERNOVA CORP. -21.98% 292 STRYKER CORPORATION -5.08% 95 872 SMITH & NEPHEW PLC -two.09% fourteen 024 INSPIRE MEDICAL SYSTEMS, INC. -0.61% half dozen 484 AXONICS, INC. seven.l% 2 829 GLAUKOS CORPORATION 24.14% 2 610

walliswhourpel.blogspot.com

Source: https://www.marketscreener.com/quote/stock/SERNOVA-CORP-25759514/news/Sernova-Announces-Clinical-Investigator-Update-of-its-Type-1-Diabetes-Trial-at-the-2022-ASTS-22nd-An-37345707/

Share this post